

CITATION REPORT

List of articles citing

Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort

DOI: 10.1002/art.24538

Arthritis and Rheumatism, 2009, 61, 830-9.

Source: <https://exaly.com/paper-pdf/46099824/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
219	Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. <i>Arthritis and Rheumatism</i> , 2009 , 60, 2757-66		64
218	Protective effect of hydroxychloroquine on renal damage may be biased: comment on the article by Pons-Estel et al. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1614; author reply 1615-6		2
217	Have some beneficial effects of hydroxychloroquine been overestimated? Potential biases in observational studies of drug effects: comment on the article by Pons-Estel et al. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1614-5; author reply 1615-6		5
216	Thrombosis in systemic lupus erythematosus: risk and protection. 2009 , 7, 1541-9		23
215	Risk factors for thrombotic events in patients with systemic lupus erythematosus from different ethnic groups. 2009 , 4, 267-269		1
214	Lupus nephritis: where are we now?. 2010 , 22, 252-6		27
213	Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. 2010 , 99, 967-74		27
212	Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. <i>Arthritis and Rheumatism</i> , 2010 , 62, 855-62		145
211	B-cell receptor for antigen modulates B-cell responses to complex TLR9 agonists and antagonists: implications for systemic lupus erythematosus. 2010 , 19, 1290-301		7
210	Therapy: Hydroxychloroquine in SLE: old drug, new perspectives. 2010 , 6, 10-1		31
209	A new role for antimalarials in systemic lupus erythematosus treatment. 2010 , 5, 299-312		1
208	The role of antimalarial agents in the treatment of SLE and lupus nephritis. 2011 , 7, 718-29		166
207	Multiethnic lupus cohorts: what have they taught us?. 2011 , 7, 3-6		42
206	Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy. 2011 , 10, 705-14		61
205	Antimalarials and SLE. 2011 , 1061-1081		0
204	SYSTEMIC LUPUS ERYTHEMATOSUS. 2011 , 315-343		20
203	[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 10. Hydroxychloroquine]. 2011 , 100, 2960-5		2

202	Epidemiology and management of refractory lupus nephritis. 2011 , 10, 655-63	44
201	Longterm followup after tapering mycophenolate mofetil during maintenance treatment for proliferative lupus nephritis. 2011 , 38, 2490; author reply 2491	1
200	Prognostic indicators of hospitalized patients with systemic lupus erythematosus: a large retrospective multicenter study in China. 2011 , 38, 1289-95	30
199	Systemic Lupus Erythematosus. 2011 , 239-259	
198	Kidney. 2011 , 769-814	8
197	Dr. Laskari, et al reply. 2011 , 38, 2491.1-2491	
196	Use of hydroxychloroquine in Japan. 2012 , 39, 1296	7
195	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. 2012 , 51, 1293-8	39
194	Chapter 12: Lupus nephritis. 2012 , 2, 221-232	53
193	References. 2012 , 2, 259-274	9
192	Predictors of survival in Chinese patients with lupus nephritis. 2012 , 21, 1049-56	37
191	Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. 2012 , 126, 76-82	280
190	Lupus nephritis. How latest insights into its pathogenesis promote novel therapies. 2012 , 24, 457-65	17
189	Outcome of patients with membranous lupus nephritis in Cape Town South Africa. 2012 , 27, 3509-15	26
188	Immunotherapies in rheumatologic disorders. 2012 , 96, 475-96, ix-x	28
187	American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. 2012 , 64, 797-808	863
186	[Lupusnephritis]. 2012 , 71, 875-84; quiz 885-6	1
185	Lupus nephritis: a critical review. 2012 , 12, 174-94	167

184	Lupus in Hispanics: a matter of serious concern. 2012 , 79, 824-34	10
183	Recent progress in the treatment of lupus nephritis. 2012 , 22, 803-813	7
182	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. 2012 , 42, 968-78	73
181	A novel pathogenetic concept-antiviral immunity in lupus nephritis. 2012 , 8, 183-9	45
180	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. 2012 , 71, 1771-82	692
179	New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. 2012 , 8, 522-33	145
178	[Diagnosis and treatment of lupus nephritis]. 2012 , 212, 147.e1-30	3
177	Lupusnephritis. 2012 , 7, 63-74	
176	Mestizos with systemic lupus erythematosus develop renal disease early while antimalarials retard its appearance: data from a Latin American cohort. 2013 , 22, 899-907	30
175	Antimalarial Medications. 2013 , 601-608	3
174	KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. 2013 , 62, 403-41	159
173	Urine biomarkers in juvenile-onset SLE nephritis. 2013 , 28, 363-74	23
172	Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. 2013 , 17, 894-906	28
171	[Treatment of systemic lupus erythematosus: myths, certainties and doubts]. 2013 , 141, 533-42	8
170	High mass resolution tissue imaging at atmospheric pressure using laserspray ionization mass spectrometry. 2013 , 352, 65-69	18
169	Biomarkers and updates on pediatric lupus nephritis. 2013 , 39, 833-53	28
168	Lupus eritematoso sistémico (II). 2013 , 11, 1966-1974	
167	Multifaceted effects of hydroxychloroquine in human disease. 2013 , 43, 264-72	88

166	Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis. 2013 , 3,	14
165	The pathogenesis of lupus nephritis. 2013 , 24, 1357-66	245
164	Race and the response to therapies for lupus: how strong is the evidence?. 2013 , 8, 471-481	3
163	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. 2013 , 40, 831-41	79
162	Review of refractory lupus nephritis. 2013 , 8, 61-72	2
161	Update on the treatment of lupus nephritis. 2013 , 22, 224-30	21
160	Systemic Lupus Erythematosus. 2013 , 803-819	
159	Renoprotective strategies in lupus nephritis: beyond immunosuppression. 2013 , 22, 1267-73	19
158	The biological and clinical activity of anti-malarial drugs in autoimmune disorders. 2013 , 9, 45-62	27
157	Renal Involvement in Children with Systemic Lupus Erythematosus. 2014 , 1-45	
156	Absence of the lysosomal protein Limp-2 attenuates renal injury in crescentic glomerulonephritis. 2014 , 92, 400-8	3
155	Treatment of membranous lupus nephritis. 2014 , 3, 106-113	1
154	Understanding Evidence-Based Rheumatology. 2014 ,	
153	Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. 2014 , 33, 649-57	23
152	Prednisone in lupus nephritis: how much is enough?. 2014 , 13, 206-14	48
151	Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. 2014 , 64, 330-7	79
150	Recent advances in the treatment of systemic lupus erythematosus. 2014 , 9, 89-100	
149	Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. 2014 , 23, 778-84	36

148	Hydroxychloroquine: a multifaceted treatment in lupus. 2014 , 43, e167-80	101
147	Update on the management of lupus nephritis. 2015 , 12, 10-15	
146	Treatment of Bullous Systemic Lupus Erythematosus. 2015 , 2015, 167064	15
145	The Diagnosis and Treatment of Systemic Lupus Erythematosus. 2015 , 112, 423-32	81
144	Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. 2015 , 2, e000089	22
143	Belimumab for the treatment of systemic lupus erythematosus. 2015 , 11, 195-204	17
142	Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. 2015 , 55, 1-21	3
141	Lupus in Latin-American patients: lessons from the GLADEL cohort. 2015 , 24, 536-45	39
140	Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study. 2015 , 35, 1225-32	8
139	Dialogue: Early predictors of long-term lupus nephritis outcomes: looking into the future. 2015 , 2, e000096	2
138	Immunsuppressive Therapie der Lupusnephritis. 2015 , 10, 24-30	
137	Reviewing the recommendations for lupus in children. 2015 , 17, 17	9
136	Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity?. 2015 , 27, 213-5	6
135	Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. 2015 , 23, 231-69	300
134	Systemic lupus erythematosus: review of synthetic drugs. 2015 , 16, 2793-806	14
133	[Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis]. 2015 , 55, 1-21	30
132	The national incidence and clinical picture of SLE in children in Australia - a report from the Australian Paediatric Surveillance Unit. 2015 , 24, 66-73	21
131	Treatment of severe lupus nephritis: the new horizon. 2015 , 11, 46-61	67

130 Value of Antimalarial Drugs in the Treatment of Lupus. **2016**, 515-520

129 Current and emerging treatment options in the management of lupus. **2016**, 5, 9-20 28

128 Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). **2016**, 95, e2891 32

127 Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis. **2016**, 68, 1295-302 58

126 Systemic lupus erythematosus diagnosis and management. **2017**, 56, i3-i13 36

125 Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry. **2016**, 68, 357-65 22

124 Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumatic drugs. **2016**, 53 Suppl 1, S58-60 3

123 Systemic Lupus Erythematosus. **2016**, 285-317.e14 15

122 Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus. **2016**, 18, 181-95 16

121 Towards new avenues in the management of lupus glomerulonephritis. **2016**, 12, 221-34 57

120 Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. **2017**, 26, 73-83 6

119 From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus. **2017**, 69, 1627-1635 26

118 Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. **2017**, 69, 1780-1788 27

117 Hydroxychloroquine retinopathy. **2017**, 31, 828-845 99

116 Chloroquine attenuates TLR3/IFN- β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis. **2017**, 27, 1004-1009 10

115 Disease characterization of systemic lupus erythematosus (SLE) patients in Quebec. **2017**, 26, 1005-1011 2

114 Outcome in biopsy-proven Lupus nephritis: Evaluation of biopsies from the Norwegian Kidney Biopsy Registry. **2017**, 26, 881-885 15

113 Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus. **2017**, 76, 1420-1425 55

112	Hydroxychloroquine alleviates persistent proteinuria in IgA nephropathy. 2017 , 49, 1233-1241	22
111	Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial. 2017 , 69, 791-799	54
110	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. 2017 , 13, 35-41	21
109	Hydroxychloroquine blood concentration in lupus nephritis: a determinant of disease outcome?. 2018 , 33, 1604-1610	18
108	Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor- κ B signaling pathway in lupus nephritis mice. 2018 , 15, 2436-2442	13
107	Double-Edged Effect of Hydroxychloroquine on Human Umbilical Cord-Derived Mesenchymal Stem Cells Treating Lupus Nephritis in MRL/lpr Mice. 2018 , 15, 1800-1813	9
106	Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis. 2018 , 13, 702-709	15
105	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. 2018 , 57, e1-e45	150
104	Pruritus in Autoimmune Connective Tissue Diseases. 2018 , 36, 267-275	4
103	Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. 2018 , 14, 693-703	99
102	An audit of the use of hydroxychloroquine in rheumatology clinics. 2018 , 2, rky013	3
101	[Lupus nephritis]. 2018 , 77, 593-608	4
100	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL,)-Pan-American League of Associations of Rheumatology (PANLAR). 2018 , 77, 1549-1557	57
99	Recent Advances in Treatment Strategies for Lupus Nephritis. 2018 , 195, 42-50	3
98	Chloroquine and amodiaquine enhance AMPK phosphorylation and improve mitochondrial fragmentation in diabetic tubulopathy. 2018 , 8, 8774	19
97	Protective effects of antimalarials in Chinese patients with systemic lupus erythematosus. 2019 , 78, e80	6
96	Clinical practice guidelines for the treatment of systemic lupus erythematosus by the Mexican College of Rheumatology. 2019 , 15, 3-20	9
95	Les traitements du lupus systémique : retour vers le futur. 2019 , 86, 573-581	

94	Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. 2019 , 209, 108274	39
93	Case 17-2019: A 44-Year-Old Man with Joint Pain, Weight Loss, and Chest Pain. 2019 , 380, 2157-2167	1
92	Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine. 2019 , 3, rkz009	7
91	Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus. 2019 , 28, 826-833	6
90	[Lupus nephritis]. 2019 , 60, 468-477	7
89	Lupus Nephritis (Including Antiphospholipid Antibody Syndrome), Pediatric. 2019 , 265-300	
88	Antimalarial Medications. 2019 , 650-660	
87	Clinical Practice Guidelines for the Treatment of Systemic Lupus Erythematosus by the Mexican College of Rheumatology. 2019 , 15, 3-20	1
86	Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus. 2019 , 22, 434-442	8
85	New therapeutic strategies in systemic lupus erythematosus management. 2019 , 15, 30-48	58
84	Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. 2019 , 86, 429-436	15
83	Response to: Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine by Michaud. 2020 , 79, e134	1
82	Pediatric Autoimmunity and Transplantation. 2020 ,	
81	Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. 2020 , 29, 52-57	10
80	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. 2020 , 262, 118541	4
79	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. 2020 , 34, e14118	2
78	Lupus nephritis: clinical presentations and outcomes in the 21st century. 2020 , 59, v39-v51	24
77	The risk of hospitalized infection in patients with systemic lupus erythematosus treated with hydroxychloroquine. 2020 , 29, 1712-1718	1

76	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. 2020 , 22, 191	8
75	An Update on the Diagnosis and Management of Lupus Nephritis. 2020 , 22, 30	8
74	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. 2020 , 60, 32	24
73	The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. 2020 , 23, 549-558	4
72	Value of antimalarial drugs in the treatment of lupus. 2021 , 591-595	1
71	Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus. 2021 , 69, 1-14	8
70	Systemic Lupus Erythematosus. 2021 , 6, 61-73	
69	Improving eye screening practice among pediatric rheumatology patients receiving hydroxychloroquine. 2021 , 30, 269-279	1
68	Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. 2021 , 60, 1774-1783	4
67	Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort: The LUMINA (Lupus in Minorities: Nature vs. Nurture) Experience (LUMINA LXXXII). 2021 , 47, 55-64	0
66	Renal System and Rheumatology. 2021 , 309-328	
65	The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug. 2021 , 8, 622225	7
64	Atualizaç�o terap�utica no LES juvenil [Refrate]. 2021 , 6-15	
63	A 6-step rapid desensitization protocol to hydroxychloroquine. 2021 , 126, 292-293	
62	Hydroxychloroquine: An Old Drug With New Tricks. 2021 , 48, 796-798	0
61	The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus. 2021 ,	7
60	Lupus Nephritis and Hydroxychloroquine-Associated Zebra Bodies: Not Just in Fabry Disease. 2021 , 3, 442-446	1
59	Hydroxychloroquine use and blood pressure below 130/80 are associated with remission in lupus nephritis: A cohort study. 2021 , 28, 109-109	

58	Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. 2021 ,	4
57	Identification of Feature Autophagy-Related Genes and DNA Methylation Profiles in Systemic Lupus Erythematosus Patients.. 2021 , 27, e933425	1
56	Hydroxychloroquine's Early Impact on Cone Density. 2021 , 2021, 1389805	
55	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. 2021 , 100, S1-S276	91
54	Glomeruläre Erkrankungen. 2017 , 69-123	1
53	Recent progress in the treatment of lupus nephritis. 2012 , 22, 803-13	2
52	Short-term Hydroxychloroquine in COVID-19 Infection in People With or Without Metabolic Syndrome - Clearing Safety Issues and Good Clinical Practice. 2020 , 16, 109-112	2
51	Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital. 2020 , 59, 2485-2490	1
50	Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?. 2019 , 15, 2-6	3
49	Current status of lupus nephritis. 2017 , 145, 167-178	7
48	Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus. 2020 , 7, S117-S120	22
47	Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues. 2019 , 8,	25
46	Lupus Nephritis. 2022 , 169-184	
45	Systemic Lupus Erythematosus and the Kidney. 2014 , 153-181	
44	Methodological Issues Relevant to Observational Studies, Registries, and Administrative Health Databases in Rheumatology. 2014 , 209-228	
43	Autoimmunerkrankungen. 2014 , 411-421	
42	Renal Involvement in Children with Systemic Lupus Erythematosus. 2015 , 1-45	
41	Renal Involvement in Children with Systemic Lupus Erythematosus. 2016 , 1449-1488	

40	Lupus Nephritis (Including Antiphospholipid Antibody Syndrome), Pediatric. 2018 , 1-35	
39	Lupus Nephritis. 2019 , 153-168	
38	Malaise, Weight Loss and Intermittent Fever. 2020 , 53-56	
37	Factors Associated with Renal Outcomes in an Inception Cohort of Biopsy-proven Lupus Nephritis Patients. 2020 , 20, 9-20	
36	75-Year-Old Man With Fever and Malaise. 2021 , 96, 2905-2910	
35	The Effect of Mycophenolate Mofetil as First-Line Therapy on the Timing of Urine Protein-to-Creatinine Ratio Reduction in Immunosuppressant-Naive Patients With Lupus Nephritis at a Single Center. 2020 , Publish Ahead of Print,	
34	Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. 2021 , 29, 1795-1805	
33	Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine.	
32	The Shifting Landscape of Lupus Nephritis Management: A Review.. 2022 , 14, e20950	0
31	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. 2022 , 14, 1759720X211073001	0
30	Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria.. 2022 , 9,	1
29	Cell Type-Specific Mechanistic Target of Rapamycin-Dependent Distortion of Autophagy Pathways in Lupus Nephritis.. 2022 ,	1
28	New Treatment Options in Lupus Nephritis.. 2022 , 70, 11	0
27	Mechanism of Action and Efficacy of Immunosuppressors in Lupus Nephritis.. 2021 , 14, 441-458	2
26	The management of lupus nephritis as proposed by EULAR/ERA 2019 versus KDIGO 2021. 2021 ,	0
25	Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.. 2022 , 1	
24	OUP accepted manuscript.	1
23	Lupus nephritis [An update on disparities affecting african americans. 2022 ,	0

- 22 Autophagy in lupus nephritis: A delicate balance between regulation and disease. **2022**, 21, 103132 ○
- 21 Recent Advances in SLE Treatment Including Biologic Therapies.
- 20 Klassifikation der Lupusnephritis.
- 19 Systemischer Lupus erythematosus und Lupusnephritis: neue Therapiestrategien. **2022**, 26, 352-358 ○
- 18 Documento de consenso del Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN) para el diagnóstico y tratamiento de la nefritis lúpica. **2022**, ○
- 17 Hydroxychloroquine suppresses anti-GBM nephritis via inhibition of JNK/p38 MAPK signaling. ○
- 16 The influence of repeated flares in response to therapy and prognosis in lupus nephritis. ○
- 15 Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: A systematic review and meta-analysis of cohort studies. 096120332211297 ○
- 14 Update on the Treatment of Glomerulonephritis in Adults in Low-to-Middle-Income Countries. 65-73 ○
- 13 Chronic kidney disease in patients with childhood-onset systemic lupus erythematosus. ○
- 12 Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: A retrospective cohort study. ○
- 11 How common is chronic kidney disease in children with lupus nephritis?. ○
- 10 Global excellence in rheumatology in Latin America: The case of systemic lupus erythematosus. 9, ○
- 9 Hydroxychloroquine Dose and Risk for Incident Retinopathy. ○
- 8 Hydroxychloroquine: Chemistry and Medicinal Applications. **2023**, 106, ○
- 7 Risk of End-stage Renal Disease in Patients with Systemic Lupus Erythematosus and Diabetes Mellitus: Danish Nationwide Cohort Study. ○
- 6 Lupus nephropathy beyond immunosuppression: Searching for nephro and cardioprotection. 3, ○
- 5 Management of Refractory Lupus Nephritis. 83-89 ○

- 4 Lupusnephritis Von der Diagnose zur Therapie. ○
- 3 Treatment of lupus nephritis: consensus, evidence and perspectives. **2023**, 19, 227-238 ○
- 2 Risk factors for subsequent lupus nephritis in patients with juvenile-onset systemic lupus erythematosus: a retrospective cohort study. **2023**, 21, ○
- 1 Risk factors for mortality in 1528 Brazilian childhood-onset systemic lupus erythematosus patients. 096120332311705